Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Leading Health Care Stock for Small-Cap Stars is Inovio Pharmaceuticals Inc. (INO) for August 21

INO, SAVA, BIOGY

Investing in small-cap health care companies can be tricky, with stocks that can soar or crash based on the results of a single clinical trial. However, equities.com's Small-Cap Stars, our proprietary list of small-cap companies with characteristics we've found to be most predictive of future success, isolates those companies that are best positioned to succeed.

Here are today's top performing health care Small-Cap Stars:

Inovio Pharmaceuticals Inc. (INO)

Inovio Pharmaceuticals Inc. gained 6.55% to $10.58. The gains came on a volume of 1,653,850 shares against an average daily volume of 1,807,203 shares. Inovio Pharmaceuticals Inc. has had a trading range from $15.80 to $5.04 over the last year, it has a 50-day SMA of $10.11, and a 200-day SMA of $10.30.

Inovio Pharmaceuticals, Inc. is a biomedical company, engaged in the development of next-generation vaccines to prevent or treat cancers and chronic infectious diseases.

Idera Pharmaceuticals Inc. (IDRA)

Idera Pharmaceuticals Inc. gained 4.67% to $2.69. The gains came on a volume of 783,996 shares against an average daily volume of 1,059,903 shares. Idera Pharmaceuticals Inc. has had a trading range from $6.87 to $1.52 over the last year, it has a 50-day SMA of $2.80, and a 200-day SMA of $3.48.

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company engaged in the discovery and development of novel synthetic DNA- and RNA- based drug candidates.

Pain Therapeutics (PTIE)

Pain Therapeutics gained 3.22% to $4.17. The gains came on a volume of 182,439 shares against an average daily volume of 209,779 shares. Pain Therapeutics has had a trading range from $6.22 to $2.46 over the last year, its P/E ratio is 7.3, it has a 50-day SMA of $4.89, and a 200-day SMA of $4.87.

Pain Therapeutics, Inc., is a biopharmaceutical company that develops novel drugs. It has four drug candidates in clinical programs, including Remoxy, Oxytrex, PTI-202 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma.

Tearlab Corporation (TEAR)

Tearlab Corporation gained 3.16% to $3.92. The gains came on a volume of 403,021 shares against an average daily volume of 378,489 shares. Tearlab Corporation has had a trading range from $13.55 to $3.30 over the last year, it has a 50-day SMA of $4.61, and a 200-day SMA of $6.57.

TearLab Corp is an in-vitro diagnostic company. It commercializes a proprietary tear testing platform that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film.

Erba Diagnostics (ERB)

Erba Diagnostics gained 3.09% to $3.00. The gains came on a volume of 46,359 shares against an average daily volume of 65,235 shares. Erba Diagnostics has had a trading range from $4.13 to $0.77 over the last year, its P/E ratio is 120.4, it has a 50-day SMA of $2.19, and a 200-day SMA of $2.31.

ERBA Diagnostics Inc develop, manufacture and market diagnostic test kits, and instrumentation in the areas of autoimmune, chemistry, hematology, diabetes and infectious diseases.

Equities.com's Health Care Small-Cap Stars - Helping You Build a Healthier Portfolio

No one can predict precisely which potential treatments will fly through their clinical trials and which will stumble along the way. At least, if someone can, they're undoubtedly spectacularly wealthy right now. But, while the science is clearly the most important factor for the success of a small-cap biotech company, it's not the only one.

Equities.com's Small-Cap Stars system uses a complicated statistical regression to determine which fundamental factors previous success stories had in common and then identifies those present health care small caps that share those traits. For health care companies, we found that a high enterprise value, a strong value line beta, and a high rate of reinvestment were among the most important qualities in predicting the potential success of a company.

All data provided by QuoteMedia and was accurate as of 4:30 pm ET.


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today